Axsome Acquires Global Rights to Late-Stage Schizophrenia Drug Balipodect, Plans Phase 3

summarizeSummary

Axsome Therapeutics has significantly expanded its neuroscience pipeline by acquiring exclusive worldwide rights to balipodect, a novel and potentially first-in-class selective PDE10A inhibitor. This acquisition adds a late-stage asset that has already completed a Phase 2 trial in schizophrenia with a favorable safety profile. The company's plan to initiate Phase 3 trial-enabling activities in 2026 for schizophrenia, along with potential development for Tourette syndrome, signals a strong commitment to advancing this promising candidate. The deal structure, involving an upfront payment, development, regulatory, and commercial milestones, plus royalties, indicates a material investment in a new growth driver for Axsome.

check_boxKey Events

• Acquisition of Balipodect Rights

  Axsome Therapeutics has entered into an asset purchase agreement with Takeda to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor.

• Pipeline Expansion & Novel Mechanism

  This acquisition expands Axsome's industry-leading CNS portfolio with a potentially first-in-class mechanism of action for neuropsychiatric conditions, including schizophrenia and Tourette syndrome.

• Phase 3 Development Planned

  Balipodect has completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia and Axsome plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026.

• Financial Terms

  Takeda received an upfront payment and is eligible for additional development, regulatory, and commercial milestone payments for the first two indications, as well as royalties on potential global net sales.

auto_awesomeAnalysis

Axsome Therapeutics has significantly expanded its neuroscience pipeline by acquiring exclusive worldwide rights to balipodect, a novel and potentially first-in-class selective PDE10A inhibitor. This acquisition adds a late-stage asset that has already completed a Phase 2 trial in schizophrenia with a favorable safety profile. The company's plan to initiate Phase 3 trial-enabling activities in 2026 for schizophrenia, along with potential development for Tourette syndrome, signals a strong commitment to advancing this promising candidate. The deal structure, involving an upfront payment, development, regulatory, and commercial milestones, plus royalties, indicates a material investment in a new growth driver for Axsome.